ArticleFrontiers in oncology2026
Integrative analysis reveals PRKCB and SRD5A2 as potential immune-associated biomarkers in prostate cancer targeted by traditional Chinese medicine.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) is a major malignant tumor that significantly threatens male health, in which various immune pathways are critically involved in its pathogenesis. This study aims to elucidate the immunomodulatory mechanisms of active constituents from 11 traditional Chinese medicines in PCa. Methods: By eliminating batch effects between the GSE69223 and GSE246282 datasets, we integrated weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) regression, protein-protein interaction (PPI) network analysis, and the CIBERSORT algorithm to identify the active components of traditional Chinese medicines and potential hub immunological biomarkers associated with immune cells. Functional enrichment analyses were conducted using the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and Gene Set Variation Analysis (GSVA). Molecular docking was employed to evaluate the interactions between active compounds and potential immunotherapeutic targets. In addition, immunohistochemistry was conducted to validate the protein expression of key targets in clinical prostate cancer tissues. Results: Among the 2,610 differentially expressed genes (DEGs) identified, PRKCB and SRD5A2 emerged as key hub genes. Notably, both genes exhibited significant correlations with immune cell infiltration and showed strong binding affinities to the active compounds kaempferol, isorhamnetin, and rhamnazin. Furthermore, functional enrichment analyses revealed the intricate involvement of the DEGs, hub genes, and candidate biomarkers in pathways closely related to immunity and prostate cancer. Finally, the expression levels of PRKCB and SRD5A2 were validated in prostate cancer and adjacent normal tissues using clinical samples. Conclusion: PRKCB and SRD5A2 were identified as potential immunological biomarkers and immunotherapeutic targets associated with immune cell infiltration in PCa, both of which were significantly downregulated in PCa tissues. Moreover, kaempferol, isorhamnetin, and rhamnazin exhibited potential immunomodulatory effects in PCa by regulating the expression of PRKCB and SRD5A2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.